Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Oncorus, Inc. (ONCR)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/28/2023 |
8-K
| Quarterly results |
| 07/19/2023 |
8-K
| Quarterly results |
| 06/09/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 06/07/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/01/2023 |
8-K
| Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm... |
| 05/18/2023 |
8-K
| Termination of a Material Definitive Agreement, Triggering Events That Accelerate or Increase a Direct Financial Obligation o... |
| 05/05/2023 |
8-K
| Quarterly results |
| 05/01/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/24/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Oncorus, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three Months Ended Year Ended December 31, December 31, 2022 2021 2022 2021 Operating expenses: Research and development $ 15,708 $ 14,276 $ 54,744 $ 44,682 General and administrative 5,072 5,586 21,793 20,136 Total operating expenses 20,780 19,862 76,537 64,818 Loss from operations Other income : Other income 285 210 Interest expense — — Interest income 309 27 911 65 Total other income , net 19 56 Net loss $ $ $ $ Comprehensive loss: Net unrealized gain on investments 21 Comprehensive loss $ $ $ $ Net loss per share - basic and diluted $ $ $ $ Weighted-average number of common shares 25,973 25,814 25,924 25,320 Oncorus, Inc. Selected Condensed Consolidated Balance Sheet Data Cash and cash equivalents..." |
|
| 03/14/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 11/30/2022 |
8-K
| Quarterly results |
| 11/02/2022 |
8-K
| Quarterly results |
| 09/14/2022 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Financial Statements and Exhibits...|
Docs:
|
"SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE is entered into as of this 13th day of September, 2022, by and between BMR-HAMPSHIRE LLC, a Delaware limited liability company , and ONCORUS, INC., a Delaware corporation . RECITALS A. WHEREAS, Landlord and Tenant are parties to that certain Lease dated as of May 10, 2016 as amended by that certain First Amendment to Lease dated as of November 17, 2016 , whereby Tenant leases certain premises from Landlord located on the fourth floor of the building at 50 Hampshire Street in Cambridge, Middlesex County, Massachusetts ; B. WHEREAS, Landlord and Tenant desire to amend the Term Expiration Date under the Existing Lease; and C. WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the condi..." |
|
| 08/05/2022 |
8-K
| Quarterly results |
| 08/04/2022 |
8-K
| Quarterly results |
| 06/23/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/04/2022 |
8-K
| Quarterly results |
| 04/05/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"WARRANT TO PURCHASE SHARES OF COMMON STOCK Company: Oncorus, Inc., a Delaware corporation Class of Shares: Common Stock, $0.0001 par value per share Number of Shares: A number equal to 2.95% of aggregate Term Loan advances actually made to the Company divided by the Warrant Price as in effect from time to time Warrant Price: $1.5126 Issue Date: April 1, 2022 Expiration Date: 10 years from the Issue Date Loan Agreement: This Warrant to Purchase shares of Common Stock is issued in connection with, and as consideration for the commitments pursuant to, that certain Loan and Security Agreement of even date herewith among the Company and certain other borrowers from time to time party thereto, K2 HealthVentures LLC, as administrative agent for lender, Ankura Trust Company, LLC, as collateral age...",
"LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT dated as of April 1, 2022 is entered into among ONCORUS, INC., a Delaware corporation , and each other Person party hereto as a borrower from time to time , K2 HEALTHVENTURES LLC as a lender, and the other lenders from time to time party hereto , K2 HEALTHVENTURES LLC, as administrative agent for Lenders , and ANKURA TRUST COMPANY, LLC, as collateral agent for Lenders . AGREEMENT Borrower Representative, each Loan Party from time to time party hereto, Administrative Agent, Collateral Trustee and Lenders hereby agree as follows: 1. ACCOUNTING AND OTHER TERMS Accounting terms not defined in this Agreement shall be construed in accordance with GAAP, and calculations and determinations shall be made following GAAP, consistently appli...",
"Oncorus Announces Debt Capital Facility with K2 HealthVentures with $20 Million Funded at Closing, Relocation of Corporate Headquarters and Extension of Cash Runway -Multiple tranche debt financing agreement provides Oncorus with access to up to $45 million- -Use of proceeds intended to support completion of a GMP-compliant manufacturing facility in Andover, MA and the clinical development of its IV administered vRNA/LNP product candidate, ONCR-021, and other pipeline programs- -Relocation of corporate headquarters to Andover facility- -Cash runway extended into early 2024- CAMBRIDGE, Mass., April 5, 2022" |
|
| 03/18/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/09/2022 |
8-K
| Quarterly results |
| 01/26/2022 |
8-K
| Other Events Interactive Data |
| 01/10/2022 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/19/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Company”), in connection with the offering by the Company of up to $50,000,000 of the Company’s common stock, par value $0.0001 per share, , pursuant to a Registration Statement on Form S-3 , filed with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Act",
"OPEN MARKET SALE AGREEMENT November 19, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022",
"Total $ 164,040" |
|
| 11/12/2021 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits ... |
| 11/09/2021 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/03/2021 |
8-K
| Quarterly results |
| 08/04/2021 |
8-K
| Quarterly results |
| 07/29/2021 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 06/21/2021 |
8-K
| Quarterly results |
| 06/15/2021 |
8-K
| Quarterly results |
| 05/27/2021 |
8-K
| Quarterly results |
|
|
|